MaaT Pharma announces the approval of its Registration Document by the French Financial Markets Authority (Autorité des marchés financiers) as part of its proposed IPO on the Euronext Paris regulated market

On October 4, 2021 MaaT Pharma S.A. (the « Company»), a French clinical stage biotech and a pioneer in the development of microbiome[1]-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported the approval of its Registration Document by the French Financial Markets Authority (Autorité des marchés financiers- AMF) under number I.21-057 on October 1, 2021 (the "Registration Document") (Press release, MaaT Pharma, OCT 4, 2021, View Source [SID1234590714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval of this Registration Document is the first step in MaaT Pharma’s proposed IPO on the Euronext Paris regulated market (the "Initial Public Offering"), subject to market conditions and the approval by the AMF of the Prospectus relating to the operation.

The Company’s existing shareholders expressed their intention to support the envisaged transaction by providing pre-commitments ahead of the launch of the IPO. These existing shareholders include Seventure Partners, Health for Life Capital, SymBiosis, Biocodex, Bpifrance, through PSIM fund and Crédit Mutuel Innovation.

Hervé Affagard, Co-founder and CEO of MaaT Pharma, said:

"MaaT Pharma aims to change the global pharmaceutical industry by developing next-generation drugs based on complete microbiome ecosystems. While 25% of the world’s population suffers from an altered gut microbiota, our clinical data show that its restoration could play a major role in improving the survival outcomes for patients with acute graft-versus-host disease (following a bone marrow transplant) as well as for patients fighting other liquid and solid tumors. Our proposed IPO comes at a pivotal time in our history, as first key development milestones have been achieved, with promising Phase 2 clinical results and the launch of a Phase 3 trial planned before year end. Based on these advances, our proprietary AI-powered and omics-based technologies, the expertise of our team and our high-precision biomanufacturing capabilities, we can now leverage these decisive advantages to pursue our growth trajectory. We expect first important milestones in the second half of 2022. We also benefit from the financial support of widely recognized international investors, who have already invested around €37 million to date, and from government bodies. We hope to address major current and future public health issues for the benefit of millions of patients."

An innovative therapeutic approach based on microbiome modulation to improve survival in patients with liquid and solid tumors
The gut microbiota is an assembly of rich and diverse microorganisms ("ecosystem") and contributes to maintain a symbiosis[2] between the host and the billions of naturally present microbes in the human body. This symbiosis is essential for human health and regulates our immune homeostasis, as 80% of immune cells reside in the intestine[3], and our metabolism. A balanced symbiosis generates protection through a stronger intestinal barrier and contributes to the education and maturation of the immune system against potential pathogens. However, lifestyle, diet, or the use of toxic drugs for the microbiome can alter this symbiosis. This alteration is referred as "dysbiosis" and is notably illustrated by a loss of diversity of microorganisms. This condition represents a danger for the host because bacteria could induce deleterious, inflammatory reactions or make anti-cancer treatments less effective.

To address major unmet medical needs in oncology, MaaT Pharma is designing a groundbreaking and revolutionary therapeutic approach based on gut microbiome modulation. The company develops high-richness and high-diversity drug candidates derived from healthy donors or produced by co-fermentation, using its MET (Microbiome Ecosystem Therapy) platform.

MaaT Pharma’s main drug candidates are:

MaaT013 for the treatment of acute graft-versus-host disease (aGvHD), ready to enter Phase 3 clinical trial (application submitted); MaaT013 is also expected to enter a Phase 2 proof-of-concept trial to evaluate its impact on response rates to immune checkpoint inhibitors in metastatic melanoma.
MaaT033 for the improvement of survival in patients receiving allo-HCT[4] consecutively to acute myeloid leukemia (AML) or other liquid tumors, currently in a Phase 1b trial.
MaaT03X, a new class of microbiome-based therapies to be used in combination with immuno-therapy in oncology, targeting solid tumors. MaaT03X is currently in preclinical testing.
MaaT013: lead microbiome therapy candidate entering Phase 3 trial for the treatment of acute Graft-vs-Host Disease (aGvHD)
In hematology-oncology, MaaT Pharma is developing MaaT013, the company’s most advanced therapy candidate. MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-from-healthy-donors[5], high-richness, high-diversity Microbiome Ecosystem Therapy, containing ButycoreTM [6] and presented as an enema[7].

MaaT013 aims to restore healthy microbiome functions in patients fighting leukemia, lymphoma, and myeloma to correct severe gut microbiota alteration due to stressors such as antibiotics and chemotherapies, and thus treat acute Graft-vs-Host disease, a severe and potentially fatal complication following an allogeneic hematopoietic stem cell transplantation (allo-HCT).

MaaT Pharma has gathered positive topline results in a Phase 2 clinical trial in patients with grade III-IV gastro-intestinal predominant aGvHD, as well as positive data from an ongoing Early Access Program taking place in France for patients having failed multiple lines of treatments. The Company expects to initiate its pivotal Phase 3 clinical trial in Europe before the year end in this indication, based on and subject to the assumptions defined by the Company in its Registration Document.

In 2018, MaaT013 was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

MaaT033: drug candidate currently in Phase 1b trial to prevent complications and improve survival after allo-HCT for patients with acute myeloid leukemia (AML) and other hematologic malignancies
MaaT033, the second therapy candidate developed in haemato-oncology, is an oral formulation with the same active substance as MaaT013. MaaT033 is designed to restore the full functionality of the gut ecosystem in order to improve survival and prevent complications following allogeneic-Hematopoietic Stem Cell Transplantation (allo-HCT) in patients with liquid tumors.

MaaT033 is currently evaluated in a dose-ranging Phase 1b clinical trial in patients with acute myeloid leukaemia (AML) following intensive chemotherapy and presenting severe dysbiosis.

If proof of concept is established with this clinical study, MaaT Pharma plans to position MaaT033 in a pivotal Phase 2/3 clinical trial, scheduled to begin in the second half of 2022. This upcoming trial will evaluate the capacity of MaaT033 to improve survival by preventing complications (notably graft-vs-host-disease and infection occurrence) for all patients undergoing an allo-HCT procedure, regardless of the cancer type.

MaaT03X: a novel class of co-fermented microbiome ecosystem therapy aiming to increase response rate to immune checkpoint inhibitors in multiple solid tumors, with the potential of large-scale production
Immune check-point inhibitors (ICI) have marked a revolution in the treatment of oncological malignancies. Despite this progress, overall response rate to ICIs remains between 20-40% in many addressed indications[8]. Notably, both the diversity and the composition of the gut microbiota have been found to increase the response rate to ICIs[9].

Based on this rationale, a Phase 2, proof of concept, trial is expected to start by the end of 2021 to evaluate the potential of MaaT013, a drug candidate designed to maximize gut microbiota’s richness and diversity, in improving the response to ICI in patients with metastatic melanoma. This study is sponsored by AP-HP and will be executed with a consortium of leading hospital and research institutions, including Institut Gustave Roussy, which will contribute as a clinical center, and INRAE, which will conduct specific analyses. MaaT Pharma will contribute by supplying MaaT013 and conducting metagenomic analyses.

In the mid-term, MaaT Pharma aims to develop synthetic products that mimic "ICI-responders" profiles, which will combine richness, diversity, and indication-specific functional bacterial networks, aiming to improve the overall response rate to ICI. The Company has designed the MaaT03X product range, which relies on the one hand, on the design of indication-specific, tailor-made full ecosystem products, by analyzing clinical data with the artificial intelligence gutPrint platform, and on the other hand on a groundbreaking co-fermentation technology, which allows to manufacture products at greater scale, in compliance with cGMP requirements. The latter exploits the natural interactions within the ecosystem to improve manufacturing quality and yields and to generate products that leverage all the functional diversity of the gut microbiome. The first MaaT03X candidate is expected to enter clinical testing in H1 2023, in combination with ICI, for the treatment of an undisclosed solid tumor with a high unmet medical need.

Microbiome Ecosystem Therapy (MET) – A proprietary platform technology to develop and manufacture product candidates at industrial scale
MaaT Pharma has now deployed one of the first global platforms that combines metagenomic data analysis and proprietary manufacturing processes to develop and manufacture drug candidates.

This development platform, called MET for Microbiome Ecosystem Therapy, stands on two pillars:

gutPrint, a proprietary computational biology platform, structured around state-of-the-art artificial intelligence and machine learning tools, which is the engine at the core of the generation of new drug candidates, based on metagenomic and biologic data collected from patients and healthy donors.
Proprietary resources and processes for cGMP manufacturing, both for native (donor-derived) products and synthetic (co-fermented) ones, supporting a versatile approach for product development, manufacturing, and industrialization, to ultimately serve hundreds of thousands of patients in multiple potential indications.

A pioneer in the microbiome field aiming to conquer high-value markets
MaaT Pharma targets oncology indications with high unmet medical need, associated with moderate to severe dysbiosis, for which the Company expects gut microbiome modulation could improve outcomes.

Acute Graft-vs-host-Disease (aGvHD) is a severe, potentially fatal disease that is a complication of allogeneic hematopoietic stem cell therapy (allo-HCT). It affects approximately 40-50% of patients receiving an allo-HCT in the 7 major markets (USA, Japan, France, Germany, Spain, Italy, and the UK), which represented approximately 10,000 incident cases in 2020 [10].

Allo-HCT is one of the most efficient ways to improve survival in patients with liquid tumors, such as acute myeloid leukemia. However, this procedure is also a factor of mortality and morbidity in these patients, as it may result in acute graft-vs-host-disease and/or be associated with infections; as such, most fragile patients are often not offered the opportunity to receive an allo-HCT. There were an estimated 22,000 allo-HCT procedures performed in the 7 major markets in 2018[11].

Immune Checkpoint Inhibitors (ICI) are some of the most used and most efficient cancer treatments, but many patients still fail to respond. The eligible population for ICI treatment in the 4 most prevalent solid cancer types (bladder cancer, non-small-cell-lung-cancer, melanoma, renal cell carcinoma) represents more than 400,000 patients[12] every year in the 7 major markets.

An ambitious development strategy
In a market with strong potentials and offering multiple opportunities, MaaT Pharma intends to pursue an ambitious strategy focused on 4 key pillars:

Focus its development on microbiome modulation in oncology (liquid and solid tumors) in indications with high unmet medical need, to maximize its expertise and consolidate its pioneer status in the microbiome field, while preserving its competitive advantage.
Gradually expand its product pipeline by discovering new innovative microbiome-based therapies in haemato-oncology and immuno-oncology, leveraging its internal expertise and its proprietary technology platform. The Company’s proprietary technology platform enables to use pre-existing clinical data to significantly accelerate new drug development and reduce associated risks. The combination of gutPrint with proprietary and exclusive cGMP manufacturing processes is used as a cornerstone to strengthen and expand the Company’s portfolio.
Build an integrated biopharmaceutical company, which could on the one hand ultimately commercialize its most advanced products, thanks to the limited number of specialized hospital centers performing allo-HCT and on the other hand establish potential collaboration agreements with one or more larger pharmaceutical partners, to develop and/or commercialize new drug candidates generated using its MET platform.
Collaborate closely with regulatory agencies to enable efficient development of a new treatment modality in this pioneering field. Since 2014, MaaT Pharma has received approval to start multiple clinical trials from the ANSM and other European agencies; MaaT013 also received Orphan Drug Designation from both the FDA and EMA in 2018. Since 2018, the French regulator ANSM has enabled access to MaaT013 in aGvHD through a compassionate use (ex-« ATU nominative ») program.
[1] The gut microbiome is constituted by all the microbes (bacteria, archaea, yeasts, viruses, …) naturally present in the gut. It plays an important role in the education and the modulation of the immune system and the metabolism.
[2] Symbiosis: mutually beneficial relationship
[3] Castro G.A. & Charles J.A., Am. J. Physiol. 265 (Gastrointest. Liver Physiol. 28): G599-G610, 1993.
[4] Allo-HCT: allogeneic hematopoietic stem cell transplant
[5] This technology combines donations from multiple strictly-vetted healthy donors to maximize richness and diversity while standardizing the product.
[6] ButycoreTM is a group of 15 different genera known to product short-chain fatty acids with anti-inflammatory properties. MaaT Pharma’s technology enables to preserve these bacteria and standardize their presence in all MaaT013 and MaaT033 products.
[7] Enema: solution for rectal administration
[8] Source: phase 3 data for Keytruda and Opdivo in certain indications
[9] Gopalakrishnan et al., Science 2018 ; Routy et al, Science 2018; Baruch et al, Science 2021, Davar et al, Science 2021
[10] Source: Global Data GvHD Epidemiology Report, January 2020
[11] Source: European Society of Blood and Marrow 18 (EBMT)
[12] Source: Global Data Epidemiology reports, 2018-2020
Availability of the Registration Document
Copies of MaaT Pharma’s Registration Document, approved by the AMF on October 1, 2021, under number I.21-057, are available free of charge and on request from the Company, at MaaT Pharma’s headquarter 70 avenue Tony Garnier, 69007 Lyon, France, as well as on the websites of the AMF (View Source) and MaaT Pharma (View Source). The Registration Document contains a detailed description of MaaT Pharma, in particular its business, strategy, financial position, and the corresponding risk factors.

Enhertu granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

On October 4, 2021 AstraZeneca reported The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens (Press release, AstraZeneca, OCT 4, 2021, View Source [SID1234590710]). Enhertu is a HER2-directed antibody drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA granted BTD based on data from the DESTINY-Breast03 Phase III trial presented during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2021. This is the second BTD for Enhertu in breast cancer and now brings the total number of BTDs to four for this medicine.

The US FDA’s BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. The new medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.

Breast cancer remains the most common cancer worldwide, with more than two million cases diagnosed in 2020, resulting in nearly 685,000 deaths globally.1 Approximately one in five cases of breast cancer are considered HER2-positive.2

Despite initial treatment with trastuzumab and a taxane, patients with HER2-positive metastatic breast cancer will often experience disease progression.3 More effective options are needed to further delay progression and extend survival.3-5

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "This is an important step in bringing Enhertu as a potential new option in earlier lines of treatment for HER2-positive metastatic breast cancer, given the urgent need to improve outcomes. This recognition by the FDA underscores the transformative possibility of Enhertu seen with the remarkable DESTINY-Breast03 results presented at ESMO (Free ESMO Whitepaper) just two weeks ago."

Ken Takeshita, Global Head, R&D, Daiichi Sankyo, said: "By granting a fourth Breakthrough Therapy Designation to Enhertu, the FDA continues to recognise the significant potential of this medicine across multiple HER2-targetable tumours. With the unprecedented data recently reported from the DESTINY-Breast03 trial, we look forward to working closely with the FDA to bring Enhertu to patients who have been previously treated for HER2-positive metastatic breast cancer as soon as possible."

In DESTINY-Breast03, Enhertu demonstrated a 72% reduction in the risk of disease progression or death compared to T-DM1 (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.22-0.37; p=7.8×10-22) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with T-DM1. Confirmed objective response rate (ORR) more than doubled in the Enhertu arm versus the T-DM1 arm (79.7% vs. 34.2%). The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified and no Grade 4 or 5 treatment-related interstitial lung disease events.

Previous BTDs for Enhertu were in late-line HER2-positive metastatic breast cancer in 2017 and HER2-mutant metastatic non-small cell lung cancer (NSCLC) and HER2-positive metastatic gastric cancer in 2020.

Enhertu is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting in the US, Japan, the EU and several other countries based on the results from the DESTINY-Breast01 trial.

Enhertu is being further assessed in a comprehensive clinical development programme evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers.

HER2-positive breast cancer
Breast cancer remains the most common cancer and is one of the leading causes of cancer-related deaths in women worldwide.1 More than two million patients with breast cancer were diagnosed in 2020, resulting in nearly 685,000 deaths globally.1 Approximately one in five cases of breast cancer are considered HER2-positive.2

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumours, including breast, gastric, lung and colorectal cancers.6 HER2 protein overexpression may occur as a result of HER2 gene amplification and is often associated with aggressive disease and a poor prognosis in breast cancer.7

Despite initial treatment with trastuzumab and a taxane, people with HER2-positive metastatic breast cancer will often experience disease progression.3 More effective options are needed to further delay progression and extend survival.3-5

DESTINY-Breast03
DESTINY-Breast03 is a global head-to-head, randomised, open-label, registrational Phase III trial evaluating the safety and efficacy of Enhertu (5.4mg/kg) versus T-DM1 in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

The primary efficacy endpoint of DESTINY-Breast03 is progression-free survival (PFS) based on blinded independent central review. Secondary efficacy endpoints include overall survival, objective response rate, duration of response, PFS based on investigator assessment and safety.

DESTINY-Breast03 enrolled approximately 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America. For more information about the trial, visit ClinicalTrials.gov.

Enhertu
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

Enhertu (5.4mg/kg) is approved in Canada, the EU, Israel, Japan, the UK and the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting based on the results from the DESTINY-Breast01 trial.

Enhertu (6.4mg/kg) is also approved in Israel, Japan and the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

Enhertu development programme
A comprehensive development programme is underway globally, evaluating the efficacy and safety of Enhertu monotherapy across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

Enhertu was highlighted in the Clinical Cancer Advances 2021 report as one of two significant advancements in the "ASCO Clinical Advance of the Year: Molecular Profiling Driving Progress in GI Cancers", based on data from both the DESTINY-CRC01 and DESTINY-Gastric01 trials, as well as one of the targeted therapy advances of the year in NSCLC, based on the interim results of the HER2-mutated cohort of the DESTINY-Lung01 trial.

Daiichi Sankyo collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialise Enhertu (a HER2-directed ADC) in March 2019, and datopotamab deruxtecan (DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for manufacturing and supply of Enhertu and datopotamab deruxtecan.

AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death.

AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment. AstraZeneca aims to continue to transform outcomes for HR-positive breast cancer with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and the next-generation oral SERD and potential new medicine camizestrant.

PARP inhibitor Lynparza (olaparib) is a targeted treatment option for metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research Lynparza in metastatic breast cancer patients with an inherited BRCA mutation and are exploring new opportunities to treat these patients earlier in their disease.

Building on the first approval of Enhertu, a HER2-directed ADC, in previously treated HER2-positive metastatic breast cancer, AstraZeneca and Daiichi Sankyo are exploring its potential in earlier lines of treatment and in new breast cancer settings.

To bring much needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is testing immunotherapy Imfinzi (durvalumab) in combination with other oncology medicines, including Lynparza and Enhertu, investigating the potential of AKT kinase inhibitor, capivasertib, in combination with chemotherapy, and collaborating with Daiichi Sankyo to explore the potential of TROP2-directed ADC, datopotamab deruxtecan.

AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

On October 1, 2021 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will be presenting three abstracts at the 2021 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting, which is being held from Nov. 10-14, both virtually and in person in Washington, D.C (Press release, Bolt Biotherapeutics, OCT 1, 2021, View Source [SID1234618694]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The three poster presentations highlight assets in Bolt’s preclinical pipeline, including two Boltbody immune stimulating antibody conjugate (ISAC) candidates and an agonist antibody. BDC-2034 is a Boltbody ISAC targeting CEA, and the other Boltbody ISAC program targets PD-L1. The company’s proprietary agonist antibody targets Dectin-2 (also known as TAM1). Information about these presentations can be found below and on the 2021 SITC (Free SITC Whitepaper) Annual Meeting website.

Title: BDC-2034: Discovery of a CEA-targeting Immune-Stimulating Antibody Conjugate (ISAC) for Solid Tumors
Presenter: William G. Mallet, Ph.D.
Poster Number: 784
Details: Saturday, Nov. 13, 2021, 7:00 a.m. – 8:30 p.m. EST, Poster Hall

Title: Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy
Presenter: Justin A. Kenkel, Ph.D.
Poster Number: 862
Details: Saturday, Nov. 13, 2021, 7:00 a.m. – 8:30 p.m. EST, Poster Hall

Title: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models
Presenter: Marcin Kowanetz, Ph.D.
Poster Number: 782
Details: Saturday, Nov. 13, 2021, 7:00 a.m. – 8:30 p.m. EST, Poster Hall

About the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) Platform

ISACs are a new category of immunotherapy that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems. Boltbody ISACs are comprised of three primary components: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant to activate the patient’s innate immune system. By initially targeting a single marker on the surface of a patient’s tumor cells, an ISAC can create a new immune response by activating and recruiting myeloid cells. The activated myeloid cells start a feed-forward loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This reprograms the tumor microenvironment and invokes an adaptive immune response that targets the tumor, with the goal of durable responses for patients with cancer.

RS Oncology, LLC, announces UK MHRA’s clinical trial acceptance of RSO-21

On October 1, 2021 RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with pleural effusion and mesothelioma, reported that acceptance of their novel drug, RSO-021, for use in a Phase 1/2 clinical trial by the Medicines and Healthcare Regulatory Agency in the UK (Press release, RS Oncology, OCT 1, 2021, View Source [SID1234597696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.

"We’re excited about RSO-021 as a novel metabolic therapy. This clinical trial is an important step in improving treatment for people living with this aggressive cancer," said RS Oncology CEO and General Counsel, Jarrett Duncan. "RSO-021, the result of a collaboration between RSO, the University of Vermont Cancer Center and Wake Forest University School of Medicine, shows tremendous promise. The treatment has shown pre-clinical efficacy in nearly a dozen different indications, signifying broad applicability and therapeutic potential for cancer therapy." "Most notably, treatments using this unique mechanism of action can be guided by a companion diagnostic, identifying patients with sufficiently dysregulated metabolic pathways prone to respond to this novel therapeutic approach." added COO and Head of business development, George Naumov, Ph.D.

RS Oncology, LLC is a preclinical stage biotechnology company based in Cambridge, Massachusetts and London, UK with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.

Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting

On October 1, 2021 Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, reported that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating AVB-500 in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting (Press release, Aravive, OCT 1, 2021, View Source [SID1234594065]). The meeting is being held November 10-14, 2021 in Washington, D.C.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
Presenter: Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive
Date: November 13, 2021
Time: 7:00 AM – 8:30 PM ET
Location: Hall E
For additional information, please visit the SITC (Free SITC Whitepaper) 36th Annual Meeting website: View Source

About the AVB-500 Phase 1b/2 ccRCC Trial
Aravive initiated the Phase 1b portion of the Phase 1b/2 trial of AVB-500 in ccRCC in March 2021. The Phase 1b portion of the clinical trial, a dose escalation study, is expected to enroll approximately 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with cabozantinib. The controlled, randomized, open-label Phase 2 portion of the clinical trial is expected to enroll approximately 45 patients and investigate the recommended AVB-500 dose identified during the Phase 1b portion of the clinical trial in combination with cabozantinib versus cabozantinib alone. The primary endpoint is progression-free survival. The trial is enrolling patients with advanced ccRCC who have progressed on front-line treatment. The Phase 1b/2 trial is listed on clinicaltrials.gov NCT04300140.

About AVB-500
AVB-500 is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian, renal and pancreatic cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. AVB-500 is currently being evaluated in multiple clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. Analysis of all safety data to date showed that AVB-500 has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals.